Platelet to lymphocyte ratio is a predictive marker of prognosis and therapeutic effect of postoperative chemotherapy in non-metastatic esophageal squamous cell carcinoma.

[1]  Z. Pan,et al.  Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival , 2017, OncoTargets and therapy.

[2]  Lu Shi,et al.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.

[3]  Hong Yang,et al.  A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the Fibrinogen/Albumin Ratio , 2017, Journal of Cancer.

[4]  Peng Zhang,et al.  Prognostic and clinicopathologic significance of neutrophil-to-lymphocyte ratio in esophageal squamous cell carcinoma: evidence from a meta-analysis , 2017, OncoTargets and therapy.

[5]  Yu-suo Tong,et al.  Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy , 2017, Scientific Reports.

[6]  Qi Zhou,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis , 2016, Scientific Reports.

[7]  M. Yashiro,et al.  The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study , 2016, BMC Cancer.

[8]  K. Hirakawa,et al.  Platelet–Lymphocyte Ratio as a Useful Predictor of the Therapeutic Effect of Neoadjuvant Chemotherapy in Breast Cancer , 2016, PloS one.

[9]  L. Shen,et al.  Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first‐line chemotherapy , 2016, Cancer medicine.

[10]  X. Xie,et al.  Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[11]  Davalyn R. Powell,et al.  Neutrophils in the Tumor Microenvironment. , 2016, Trends in immunology.

[12]  Q. Song,et al.  The clinical significance of systemic inflammation score in esophageal squamous cell carcinoma , 2016, Tumor Biology.

[13]  Osamu Kikuchi,et al.  Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. , 2015, Gastroenterology.

[14]  Ying Huang,et al.  A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma. , 2015, American journal of cancer research.

[15]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[16]  Ying Huang,et al.  Lymphopenia Predicts Poor Prognosis in Patients With Esophageal Squamous Cell Carcinoma , 2014, Medicine.

[17]  Shuling Chen,et al.  The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis , 2014, Journal of Cancer Research and Clinical Oncology.

[18]  I. Tannock,et al.  Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[19]  Y. Qiao,et al.  Epidemiology of Esophageal Cancer in Japan and China , 2013 .

[20]  Laurie J. Gay,et al.  Contribution of platelets to tumour metastasis , 2011, Nature Reviews Cancer.

[21]  C. Holmes,et al.  The platelet contribution to cancer progression , 2011, Journal of thrombosis and haemostasis : JTH.

[22]  Roger Newson,et al.  Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .

[23]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[24]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[25]  M. Kitajima,et al.  The Influence of Platelets on the Promotion of Invasion by Tumor Cells and Inhibition by Antiplatelet Agents , 2004, Pancreas.

[26]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[27]  W. Jelkmann,et al.  Role of blood platelets in infection and inflammation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[28]  C. McArdle,et al.  The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer , 2002, British Journal of Cancer.

[29]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[30]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[31]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[32]  G. Kōsaki,et al.  [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. , 1984, Nihon Geka Gakkai zasshi.